Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 49-54

  Greenhalgh, J ^a   Bagust, A ^b   Boland, A ^b   Fleeman, N ^b   McLeod, C ^b   Dundar, Y ^b   Proudlove, C ^b   Shaw, R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY;

COST BENEFIT ANALYSIS; ECONOMICS; HEAD AND NECK TUMOR; HUMAN; METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886943080     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/08     Document Type: Review

References (8)